HC Wainwright Has Pessimistic View of Cibus FY2029 Earnings

Cibus, Inc. (NASDAQ:CBUS) – Stock analysts at HC Wainwright dropped their FY2029 EPS estimates for Cibus in a note issued to investors on Friday, August 14th. HC Wainwright analyst A. Dayal now forecasts that the company will earn $0.27 per share for the year, down from their prior estimate of $0.28. The consensus estimate for Cibus’ current full-year earnings is ($1.13) per share. HC Wainwright also issued estimates for Cibus’ FY2030 earnings at $2.08 EPS.

A number of other research analysts have also recently issued reports on CBUS. Wall Street Zen upgraded Cibus from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. Weiss Ratings cut Cibus from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, June 29th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $9.00.

Cibus Stock Down 2.4%

Shares of CBUS opened at $1.63 on Monday. The stock has a market cap of $124.42 million, a P/E ratio of -0.99 and a beta of 1.61. The business’s 50 day moving average price is $1.67 and its 200-day moving average price is $1.97. Cibus has a 52 week low of $1.09 and a 52 week high of $4.19.

Cibus (NASDAQ:CBUS) last released its earnings results on Thursday, August 13th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.10). Cibus had a negative net margin of 2,258.89% and a negative return on equity of 287.03%. The business had revenue of $0.99 million for the quarter, compared to analysts’ expectations of $1.70 million.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. PACK Private Wealth LLC purchased a new stake in shares of Cibus during the fourth quarter valued at approximately $27,000. Dimensional Fund Advisors LP purchased a new position in Cibus in the 1st quarter worth approximately $33,000. Qube Research & Technologies Ltd bought a new position in Cibus in the 2nd quarter valued at approximately $39,000. Rockland Trust Co. bought a new position in Cibus in the 2nd quarter valued at approximately $41,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in Cibus during the 1st quarter valued at $66,000. Institutional investors own 33.81% of the company’s stock.

Cibus Company Profile

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships.